Clinical trial
A Phase 1, Open-label Drug Interaction Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
NCT05692570 is registered in ClinicalTrials.gov with Pyramid Biosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label Drug Interaction Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
- Lead sponsor
- Pyramid Biosciences
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 9, 2022
- Completion date
- November 12, 2022
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
drug-drug interaction